Vaccines and antidiabetics lead the charge for Japanese market growth
This article was originally published in Scrip
Executive Summary
Japan's prescription market rose by a solid 7.7% to ¥2,332.3 billion ($30.25 billion) at official reimbursement prices in the July-September quarter, helped by the lack of a regular biennial price cut in April and strong growth for antidiabetics and vaccines.